CapVest-backed Curium to acquire Lantheus for up to $8 billion
The transaction would combine complementary radiopharmaceutical diagnostics and therapeutics businesses serving patients in more than 70 countries.
Takeaways
- Curium agreed to acquire Lantheus for up to approximately $8 billion.
- CapVest remains Curium's controlling shareholder.
- The companies expect the transaction to close in the first half of 2027.
CapVest-backed Curium entered a definitive agreement to acquire Lantheus in a transaction valued at up to $8 billion.
Lantheus shareholders would receive $102.50 per share in cash at closing and contingent value rights worth up to another $12 per share.
The combination would join Curium's radiopharmaceutical manufacturing and therapeutics portfolio with Lantheus' U.S. radiodiagnostics business.
The companies expect the transaction to close in the first half of 2027, subject to shareholder and regulatory approvals.
Get Buyout Desk email updates.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up on the site. Email updates are not on a fixed schedule.